Teva appoints former Dyax executive
JERUSALEM — Teva Pharmaceutical Industries has appointed a former executive from Dyax to its executive team, the Israeli generic drug maker said.
Teva announced the appointment of Ivana Magovčević-Liebisch as SVP and head of corporate business development, effective April 1. Magovčević-Liebisch served as EVP and COO for Dyax, a Burlington, Mass.-based drug company.
"Teva continues to build its premier leadership team, and we anticipate that Ivana, with her track record in partnering and licensing agreements and her extensive industry experience from R&D to commercial operations, will play an important role in the ongoing success of our business development programs," Teva group EVP human resources and chief integration officer Ika Abravanel said.
Sagent appoints James Hussey as president
SCHAUMBURG, Ill. — Generic drug maker Sagent Pharmaceuticals has appointed James Hussey as its president, the company said.
Sagent said the board of directors’ appointment of Hussey, 53, would be effective Monday. Hussey will be responsible for the company’s commercial operations, including development, regulatory affairs, supply chain activities, sales, marketing and human resources.
"We are delighted to have Jim join the organization as our president," Sagent CEO and chairman Jeffrey Yordon said. "Given the growth trajectory we have experienced and our projected performance going forward, we want to provide seasoned leadership to our commercial operations while I continue to drive strategic development, develop partner relationships and investigate vertical integration."
Sandoz launches generic contraceptives
PRINCETON, N.J. — The Food and Drug Administration has approved and launched two generic contraceptives made by Sandoz, the drug maker said.
Sandoz, the generics division of Swiss drug maker Novartis, announced the approval of Estarylla (norgestimate and ethinyl estradiol tablets) and Tri-Estarylla (norgestimate and ethinyl estradiol tablets), generic versions of Johnson & Johnson’s Ortho Cyclen and Ortho Tri-Cyclen, respectively. Sandoz said the launches brought the total number of oral contraceptives it has launched since the beginning of 2011 to six.
"We are pleased to add two more products to our portfolio of oral contraceptives," Sandoz president Don DeGolyer said. "Sandoz is committed to helping meet the needs of women in the U.S. by providing cost-saving, high-quality options for women’s healthcare."
Ortho Cyclen and Ortho Tri-Cyclen had sales of $116 million and $240 million, respectively, during the 12-month period that ended in January 2013.